Evaluating global coagulation assays in patients with venous thromboembolism

Jeffrey Lai¹, Hui Yin Lim^{1,2}, Prahlad Ho^{1,2}, Julie Wang^{1,2}

1 University of Melbourne, Victoria, Australia 2 Department of Haematology, The Northern Hospital, Victoria, Australia




Background and methods

- Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a prevalent disease worldwide associated with high recurrence, significant morbidity and mortality¹.
- Current routine coagulation tests cannot reliably predict recurrence, although abnormal D-dimer level is associated with high risk of recurrence².
- **Global coagulation assays (GCA)** may provide a holistic evaluation of total clot formation and lysis³ and we hypothesise that they may have utility in risk stratification of VTE recurrence in clinical setting. Such assays include:
 - Calibrated automated thrombogram (CAT) evaluates thrombin generation
 - Overall haemostatic potential (OHP) assay evaluates fibrin generation

Naess IA et al. Journal of thrombosis and haemostasis. 2007;5(4):692-9.
Palareti G et al. The New England journal of medicine. 2006;355(17):1780-9
Lim HY et al. Thrombosis research. 2019;179:45-55.

- VTE patients and healthy normal controls were recruited at the Northern Hospital.
- For normal controls, blood was collected once only.
- For VTE patients, blood was collected at two different timepoints described in the diagram below.
- Baseline blood tests were performed. CAT and OHP were performed on platelet-poor plasma, obtained by double centrifugation.
- Patients were followed up for a median of 19 months.
- The focus of this poster presentation is the patient subgroup who have ceased anticoagulation after initial treatment.



Evaluating global coagulation assays in patients with venous thromboembolism

Jeffrey Lai¹, Hui Yin Lim^{1,2}, Prahlad Ho^{1,2}, Julie Wang^{1,2}

1 University of Melbourne, Victoria, Australia 2 Department of Haematology, The Northern Hospital, Victoria, Australia



Results and discussion

OHP of subjects and controls at Timepoint 1 and 2





Figure 1. Standard OHP assay curve.

OCP: overall coagulation potential – amount of fibrin generated, reported as area under OCP curve

OHP: overall haemostatic potential – balance of fibrin generation and lysis, reported as area under OHP curve


OFP: overall coagulation potential – amount of fibrin lysed, reported as a percentage difference between OCP and OHP




* Multivariate analysis (age and gender adjusted) compared to normal controls, p < 0.05

Figure 2. OHP at Timepoint 1 and 2 (TP1 & TP2).

- Elevated OHP and reduced OFP at both TP1 and TP2 when compared to control (9.5 and 9.6 vs 6.4, 75.5% and 74.8% vs 81.2%, respectively).
- Results indicate there is persistently elevated thrombin generation and hypofibrinolysis in VTE subjects compared to normal controls.



CAT of subjects and controls at Timepoint 2



Normal Subject

(TP2)

control

Figure 3. Standard CAT assay curve.

Lag time: time until thrombin generation

Endogenous thrombin potential (ETP): amount of thrombin generated, area under the curve

Peak thrombin: maximum concentration of thrombin

Velocity index: maximum rate of thrombin generation

Figure 4. CAT at Timepoint 2 (TP2) after anticoagulation cessation compared to normal controls.

- Shortened lag time at TP2 compared to controls (3.9 min vs 5.9 min), suggesting a more rapid thrombin generation.
- No significant difference in ETP, peak thrombin and velocity index when compared to controls.

* Multivariate analysis (age and gender adjusted) compared to normal controls, p < 0.05 Northern Health

Evaluating global coagulation assays in patients with venous thromboembolism

Jeffrey Lai¹, Hui Yin Lim^{1,2}, Prahlad Ho^{1,2}, Julie Wang^{1,2}

1 University of Melbourne, Victoria, Australia 2 Department of Haematology, The Northern Hospital, Victoria, Australia



Results and discussion (cont.), Conclusion

GCA of patients with and without VTE recurrence




Figure 5. Peak thrombin and velocity index at Timepoint 2 (TP2) for patients with and without VTE recurrence

- **Higher peak thrombin** (259 vs 212 nM) and **velocity index** (83.9 vs 59.5 nM/min) at TP2 (anticoagulation ceased) in those who developed VTE recurrence, compared to those that did not.
- No significant difference in OHP assay between the two groups.
- * Univariate analysis compared to no recurrence group, p < 0.05

Conclusions

- Patients who later developed recurrent VTE displayed significantly higher peak thrombin and velocity index 4-6 weeks after cessation of anticoagulation, compared to those who did not develop recurrent VTE.
- Compared to normal controls, VTE patients display increased thrombin generation and reduced fibrinolysis as demonstrated by CAT and OHP.

Acknowledgment

Thank you to Mark Tacey for the help in statistical analysis, my fellow medical student Anna Kwok and my supervisors at the Haematology Department, Northern Health for their support, as well as Bristol Myers Squibb-Pfizer Alliance for supporting this project.

Northern Health